Bispecific antibodies play an increasingly important role in the therapeutic antibody space today.
A major challenge in the field is the assembly of the correct heterodimer once two antibodies have been identified. Ligand Pharmaceuticals has addressed this problem by engineering a chicken that expresses a common light chain, thereby conferring epitope specificity entirely on the expressed heavy chain. As a host animal for immunization, the chicken offers many advantages including the ability to recognize highly conserved targets that are poorly immunogenic in mammals.
Presented by Kathryn H. Ching, PhD, Research Investigator, Ligand Pharmaceuticals